## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($170.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know**
- Source: Markets Financial Content | 20251203T215500 | Bullish | Relevance: 100%
- Shares of Charles River Laboratories (CRL) jumped 6.1% after the company provided an encouraging business update at an investor conference, highlighting positive demand trends in its Discovery and Safety Assessment (DSA) segment. The company reported that its net book-to-bill ratio has risen each month since the start of the third fiscal quarter, leading to optimism about upward trends despite potential short-term holiday seasonality. CRL shares closed at $184.69, reflecting a 5.7% increase, and are trading near their 52-week high.

**2. Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know**
- Source: Finviz | 20251203T165500 | Bullish | Relevance: 100%
- Charles River Laboratories (CRL) shares jumped 6.1% after the company provided an encouraging business update at an investor conference, highlighting positive demand trends in its Discovery and Safety Assessment (DSA) segment. The company reported that its net book-to-bill ratio has risen each month since the start of the third fiscal quarter, leading to optimism despite potential holiday seasonality. The stock closed at $184.69, up 5.7% from the previous close, reflecting a significant market reaction to the positive news.

**3. Charles River Laboratories International Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163000 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. stock (CRL) rose 5.67% on Wednesday, closing at $184.67. This performance outpaced broader market gains, with the S&P 500 and Dow Jones Industrial Average also seeing positive movement. The stock's increase ended a three-day losing streak for the company.

**4. New York State Common Retirement Fund Reduces Position in Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251204T121008 | Neutral | Relevance: 100%
- The New York State Common Retirement Fund has decreased its stake in Charles River Laboratories International (NYSE: CRL) by 15.8% in the second quarter, selling 20,812 shares. Despite this, analysts maintain a "Moderate Buy" rating for CRL with an average price target of $190.86, following strong earnings results and recent upgrades from firms like Barclays and Baird. The company exceeded revenue and EPS estimates in its latest quarter, though it posted a negative net margin.

**5. JPMorgan Chase & Co. Sells 481,286 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251204T101446 | Somewhat-Bullish | Relevance: 100%
- JPMorgan Chase & Co. significantly reduced its stake in Charles River Laboratories International (NYSE:CRL) during the second quarter, selling 481,286 shares and retaining 277,106 shares valued at approximately $42.05 million. Analyst sentiment for Charles River remains largely positive, with a "Moderate Buy" consensus and an average price target of $190.86. The company recently reported strong quarterly earnings, beating EPS and revenue estimates.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $185 | $170 | +9% |
| 2025-11-10 | TD Cowen | $197 | $205 | -4% |
| 2025-11-06 | JP Morgan | $165 | $160 | +3% |
| 2025-11-06 | Barclays | $210 | $195 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |
| 2025-11-10 | TD Cowen | main | Buy |
| 2025-11-06 | JP Morgan | main | Neutral |
| 2025-11-06 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 16.8x stretched relative to 7% growth. Analyst sentiment positive (4 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $204.47 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 16.8 |
| Current P/E | 18.0 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.9% (minimal 5-day change). Below STRENGTH zone by 0.1pp (needs >3.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. Outperforming sector by 4.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.74), confirming momentum. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.86% (CS: 79) | Neutral |
| RSI_14 | 62.3 | Neutral |
| MACD Histogram | 1.74 | Bullish |
| vs SMA20 | 1.073x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.181x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $184.04
- **Stop Loss:** $170.64 (7.3% risk)
- **Target:** $197.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $6,809.48
- **Portfolio %:** 6.81%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*